MAGEH1: A Protein Implicated in Disease (G28986)

Target Name: MAGEH1

NCBI ID: G28986

MAGEH1

MAGEH1: A Protein Implicated in Disease

MAGEH1, also known as MAGE-A1, is a protein that belongs to the MAGE family of proteins. This family of proteins plays a crucial role in the immune response and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the main functions of MAGEH1 is its role in the development and regulation of inflammation. MAGEH1 has been shown to be involved in the regulation of immune cell function and in the development of autoimmune diseases.

In addition to its role in inflammation, MAGEH1 has also been shown to be involved in the regulation of cell death and has been linked to a number of diseases, including cancer.

MAGEH1 has also been shown to be involved in the regulation of cell adhesion and has been implicated in the development of diseases that are characterized by the disruption of cell adhesion, such as cancer.

MAGEH1 has also been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival and is a key factor in the development and progression of many diseases.

MAGEH1 has also been shown to be involved in the regulation of cell cycle progression and has been implicated in the development of many types of cancer.

In conclusion, MAGEH1 is a protein that has been shown to be involved in a number of important functions in both normal and disease. As a drug target or biomarker, MAGEH1 has the potential to be a valuable tool for the development of new treatments for a wide range of diseases.

Protein Name: MAGE Family Member H1

The "MAGEH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets